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About 7% of all cases of cancer in Denmark are haema-
tological malignancies (1). The diagnosis of a haemato-
logical malignancy and its treatment potentially lead to
symptoms and problems that affect quality of life. An
important task of the health care system is to assess,
monitor, and prevent such symptoms and problems in
order to help patients live as fully as possible with their
disease (2, 3). This has only become more relevant as the
survival has increased (4, 5), and the task is particularly
important for diseases that may not be curable (6).
Despite a general acknowledgement of the importance
of the patients’ health related quality of life (HRQOL)
relatively few studies have investigated this issue in hae-
matological patients (4, 6–9). In 2005 a review found
only eight studies investigating HRQOL in patients with
chronic lymphocytic leukaemia (CLL), which is the most
common leukaemia in adults. None of the identiﬁed
studies investigated patients who had never received
treatment, measured quality of life in a random sample
of CLL patients, or had quality of life as their primary
objective (10). Potential reasons for the lack of studies of
HRQOL in patients with CLL may be that many of
these patients are expected to live a quite normal life
(11), and that a large proportion of these patients are
observed untreated or receive a treatment of moderate
toxicity, and HRQOL outcomes may therefore be
deemed less important (12). The picture of few studies is
the same for acute leukaemia, but for these patients the
reason may be that the diseases are very acute and there-
fore HRQOL studies are perhaps not considered feasible
(8, 13). Similarly only few studies of HRQOL have been
conducted for multiple myeloma (14).
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have either focused on long-term survivors or have been
part of clinical trials investigating different treatment
regimens. To our knowledge, there exist no study
assessing HRQOL in the entire group of haematological
patients seen in hospitals. Such a study would provide
clinically valuable information. It would speciﬁcally
answer the two simple questions: to what extents are
haematological patients burdened by symptoms and
problems that deserve attention? And which groups of
patients suffer from which symptoms and problems?
This study was part of a larger study assessing symp-
toms and problems in patients with advanced cancer
deﬁned as patients with TNM stages 3 or 4 (TNM: sys-
tem for classifying cancers; T = local tumour growth,
N = regional lymph nodes, M = metastasis) (the results
concerning patients with solid tumours will be reported
elsewhere). However, the TNM system is not fully appli-
cable to haematological malignancies. Thus, the TNM
system was employed for lymphoma but not for patients
with leukaemia and multiple myeloma.
In the present study we therefore investigated HRQOL
of adult patients with lymphoma in stage 3 or 4, and
patients with multiple myeloma or leukaemia in any
stage. The study was conducted as a nationally represen-
tative, cross-sectional study with the following aims: (i)
to measure symptoms and problems; and (ii) to identify
predictors of symptoms and problems.
Method
Patients
All clinical hospital departments (except for departments
of psychiatry and paediatrics) from three out of 14 regions
across Denmark (total population 5.5 millions) were
invited to participate (n = 81). The three regions were
selected to represent Denmark concerning geographic and
demographic characteristics. In each participating depart-
ment all cancer patients born from the 1st to the 22nd in
the month were identiﬁed from the patient register. An
exception was made for four departments where a smaller
proportion of patients were selected (fewer birth days were
included). This leads to a slight under-representation of
patients from these departments, but since only few
patients with haematological malignancies were identiﬁed
from these departments this has no practical implications.
Only patients who had been in contact with the hospital
department within the past year, and lived in one of the
three regions were retrieved from the registers.
Medical students reviewed the medical records of all
patients in the retrievals. Patients were included if they
had lymphoma stage 3 or 4 or leukaemia or multiple
myeloma. Patients were excluded if they did not speak
Danish, had a cognitive impairment or had a psychiatric
co-morbidity.
Included patients received an information letter, a con-
sent form, and a questionnaire by mail. A reminder was
sent after 2 weeks. The study was approved by the local
ethics committee (01-116⁄03 and 11-143⁄03) and took
place from October 2004 to January 2006.
Clinical data and assessments
The following clinical data were extracted from the medi-
cal records: gender, age, diagnosis, stage of disease for
lymphomas [using the American Joint Committee on
Cancer (AJCC) manual (15)], time of (ﬁrst) diagnosis,
contact type (latest contact with the hospital: out-patient
or hospitalised), and treatment status (in active antineo-
plastic treatment or not).
Participants received the EORTC QLQ-C30 (16, 17)
questionnaire assessing health-related quality of life. It
consists of ﬁve multi-item function scales: physical, role,
emotional, cognitive, and social function; a global health
status⁄quality of life (QOL) scale; three multi-item symp-
tom scales: fatigue, nausea and vomiting, and pain; and
six single-item symptom scales: dyspnoea, insomnia,
appetite loss, constipation, diarrhoea and ﬁnancial difﬁ-
culties. For the ﬁve function scales and global health sta-
tus⁄QOL higher scores represent better functioning.
Conversely, for the nine symptom scales higher scores
represent more symptoms.
Statistics
The analyses were performed using sas statistical soft-
ware version 9 (SAS Institute Inc., Cary, NC, USA) (18).
Participants and non-participants were compared using
Wilcoxon (age, time since diagnosis), chi-square (region,
type of departments, diagnosis) and Fisher’s exact tests
(gender, treatment status, contact type).
The responses to the EORTC QLQ-C30 were converted
into 0–100 scales according to the scoring manual, and
mean scores were calculated (17). For the EORTC QLQ-
C30 there are no predeﬁned thresholds for when a symp-
tom or function score should be interpreted as a case.
However, to ease clinical interpretation of the data, and in
accordance with previous procedures (19), we
dichotomised the scores using two thresholds: (i) we
calculated frequencies of ‘symptoms⁄problems’ and
deﬁned that a patient had a ‘symptom⁄problem’ if the
scale score corresponded to at least ‘a little’ (symptom
scale ‡ 33, function scale £ 67); and (ii) we calculated fre-
quencies of ‘severe symptoms⁄problems’ and deﬁned that
a patient had a ‘severe symptom⁄problem’ if the score cor-
responded to at least ‘quite a bit’ (symptom scale ‡ 66,
function scale £ 34) (see Fig. 1). This was done for all
HRQOL in haematological patients Johnsen et al.
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lated the number of ‘symptoms⁄problems’ and ‘severe
symptoms⁄problems’ for each person. These numbers
include both symptom scales and function scales, but
exclude the global health status⁄QOL scale, and thus
range from 0–14.
We used ordinal logistic regression to identify the predic-
tors of symptoms and loss of function. We used a stepwise
procedure with inclusion⁄exclusion criteria of P = 0.01.
The following clinical and sociodemographic variables
were tested: gender, age, diagnosis, time since diagnosis,
contact type, treatment status, type of department, region,
formal education, children and marital status.
Results
Patients
Figure 2 shows the inclusion process. In total, 56 (69%)
of the invited hospital departments participated (27
departments of surgery, 23 departments of medicine, four
departments of oncology and two departments of haema-
tology), and from their patient registers we were
provided with lists of 8217 patients. From 19 of the 25
non-participating departments we were provided with
retrievals containing 686 additional patients. Hence, we
could have reviewed 8% more medical records if they
had participated too. None of the non-participating
departments were departments of haematology, oncol-
ogy, or internal medicine. We reviewed the medical
records of 7661 of the 8217 patients. The remaining 556
(7%) medical records were not reviewed because they
were impossible to get a hold on after several attempts
(e.g. the medical record was misplaced or stored in an
achieve another place).
Of the 7661 medical records reviewed, 1225 patients
were identiﬁed as having a haematological malignancy.
Of these, we excluded 61 because they had not had con-
tact to the department within the previous year; 269
because they had lymphoma stage 1 or 2; 60 because
stage of lymphoma was inaccessible; and 34 because they
had a cognitive impairment, had a psychiatric illness, or
did not speak Danish. Of the 801 patients included, 54
did not receive a questionnaire because of administrative
failure, and 15 died before receiving a questionnaire.
Thus, questionnaires were sent to 732 patients represent-
ing 19 hospital departments. In total, 470 (64%) patients
returned a completed questionnaire.
Characteristics of participants and non-participants
can be seen in Table 1. Compared to non-participants,
participants were younger (mean age 63 years vs.
66 years), and were less likely to have a diagnosis of
CLL and non-Hodgkin’s lymphoma.
Symptoms and problems
Table 2 shows the mean scores for the symptom and
function scales, and the percentages of patients having a
Functional scale range 
Severe  
symptom/problem
Symptom/problem 
Symptom scale range 
34  100 
66  33  0
67  0
100
Figure 1 Illustration of deﬁnition of ‘symptom⁄problem’ and ‘severe
symptom⁄problem’.
Patients in retrieval
n = 686
No, but provided a retrieval
n = 19
Medical records not reviewed
n = 556
No heamatological malignancy
6436
Contact > 1 year
n = 61
Lymphoma stage 1 or 2
n = 269
Excluded patients
n = 34
Died before questionnaire
n = 15
Non participants
n = 262
Participants
n = 470
Received questionnaire
n = 732
Administrative failure
n = 54
Included patients
n = 801
n = 835
Stage of lymphoma inassessable
n = 60
Contact < 1 year
n = 1164
Heamatological malignancy
n = 1225
Medical records reviewed
n = 7661
Patients in retrieval
n = 8217
Yes, n = 56 No, n = 6
Wish to participate
Invited hospital wards
n = 81
Relevant diagnosis or stage of disease
Figure 2 Inclusion of patients.
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and for each diagnosis. The symptom with the highest
mean score (indicating most symptoms) was fatigue, fol-
lowed by pain and insomnia. The function scale with the
lowest mean score (indicating the most severe impair-
ment) was role function, followed by physical function.
Using the cut-off values, 55% of the patients had fatigue
(20% severely), 49% reduced role function (23%
severely), 46% insomnia (15% severely), and 37% pain
(15% severely). The mean number of ‘symptoms⁄prob-
lems’ was 4.3, and the mean number of ‘severe symp-
toms⁄problems’ was 1.5. In total, 82% of the patients
had at least one ‘symptom⁄problem’, and 45% had at
least one ‘severe symptom⁄problem’.
There were signiﬁcant differences in the levels of physi-
cal function, role function, social function, pain, and
constipation across the diagnoses (P-values not shown in
Table 2). Generally, patients with multiple myeloma had
most symptoms and problems. The mean number of
‘symptoms⁄problems’ ranged from 3.7 acute myeloid
Table 1 Characteristics of participants and non-participants
Characteristics
Participants Non-participants
P-value N % N %
No. of patients 470 64 262 36
Age, mean 470 63 262 66 0.02
Gender Male 248 53 133 51 0.70
Female 222 47 129 49
Primary tumour site AML 34 7 9 4 0.02
CLL 132 28 92 35
CML 34 7 8 3
Hodgkin lymphoma 33 7 11 4
Non-Hodgkin lymphoma 164 35 102 39
Multiple myeloma 54 11 32 12
Other
1 19 4 8 3
Time since diagnosis 0–6 months 57 13 23 9 0.45
6–12 months 35 8 23 9
1–2 years 64 14 49 20
2–5 years 124 28 56 22
5–10 years 111 25 61 24
>10 years 59 13 38 15
Ongoing treatment Yes 99 22 59 23 0.71
No 358 78 199 77
Contact type Hospitalised 24 5 19 7 0.25
Out-patients 439 95 242 93
Department Haematological 405 86 222 84 0.70
Medical 52 11 34 13
Other
2 13 3 6 2
Region Copenhagen 206 44 121 46 0.19
Ringkoebing 32 7 26 10
Funen 232 49 115 44
Formal education
3 None 66 17 – –
Semi-skilled worker⁄short
education (<1 year)
52 13 –
Skilled worker 39 10 –
Short theoretical (1–3 years) 57 15 –
Long theoretical (>3 years) 133 34 –
Academic 46 12 –
Civil status
3 Married⁄cohabiting 291 63 – –
Divorced⁄separated 54 12 –
Unmarried 46 10 –
Widow⁄widower 68 15 –
Children
3 Yes 386 84 – –
No 76 16 –
CLL, chronic lymphocytic leukaemia; CML, chronic myeloid leukaemia; AML, acute myeloid leukaemia.
1Patients with ALL, myeloﬁbrosis or unclassiﬁed leukaemia.
2Patients from departments of surgery and oncology.
3These variables were assessed in participants only.
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ª 2009 John Wiley & Sons A ⁄ S 143leukaemia (AML) to 5.6 (multiple myeloma); ‘severe
symptoms⁄problems’ ranged from 0.9 (AML) to 2.3
(multiple myeloma).
Predictors
Results of the multivariate logistic regressions can be
seen in Table 3. Older patients were more reduced in
physical and role function, had lower quality of life, and
more constipation, appetite loss and pain than younger
patients, but less ﬁnancial difﬁculties. Women had lower
physical function, and more insomnia than men.
Recently hospitalised patients had more nausea and
appetite loss than out-patients. Patients in active treat-
ment had more reduced physical function, lower quality
of life, and more appetite loss and fatigue than patients
not in active treatment. Patients from departments of
medicine had lower quality of life and more fatigue, than
Table 3 Predictors of symptoms and problems of the EORTC QLQ-C30 using ordinal logistic regression
Scale Predicting variable(s)
1 OR
2 (95% CL) P
Physical function Age (per 10 year) 1.53 (1.36–1.74) <.001
Sex (male vs. female) 0.58 (0.42–0.80) 0.001
Active treatment (yes vs. no) 1.87 (1.26–2.79) 0.002
Role function Age (per 10 year) 1.32 (1.16–1.51) <.001
Diagnosis: 0.002
CLL 1.01 (0.66–1.55)
CML 1.24 (0.62–2.47)
AML 1.14 (0.56–2.31)
Hodgkin lymphoma 1.36 (0.67–2.78)
Non-Hodgkin lymphoma 1.00 –
Multiple myeloma 3.25 (1.86–5.67)
Other 2.03 (0.83–4.97)
Emotional function No signiﬁcant predictors
Social function No signiﬁcant predictors
Cognitive function Education:
None 1.79 (0.94–3.42) 0.005
Semi-skilled worker (<1 yr) 1.23 (0.62–2.45)
Skilled worker 1.02 (0.49–2.17)
Short theoretical (1–3 years) 1.00 –
Long theoretical (>3 years) 0.71 (0.40–1.28)
Academic 0.51 (0.24–1.08)
Age (per 10 year) 1.18 (1.05–1.32) 0.006
Quality of life Active treatment (yes vs. no) 1.96 (1.31–2.92) 0.001
Department:
Haematology 1.00 – 0.007
Medicine 2.13 (1.23–3.69)
Other 2.43 (0.92–6.34)
Fatigue Active treatment (yes vs. no) 1.85 (1.25–2.74) 0.002
Department:
Haematology 1.00 – 0.006
Medicine 1.82 (1.06–3.12)
Other 3.43 (1.30–9.05)
Pain Age (per 10 year) 1.28 (1.13–1.45) <.001
Nausea⁄vomiting Contact type (hospitalised vs. out-patient) 2.98 (1.30–6.83) 0.010
Dyspnoea No signiﬁcant predictors
Appetite loss Age (per 10 year) 1.28 (1.08–1.51) 0.004
Active treatment (yes vs. no) 2.03 (1.25–3.29) 0.004
Contact type (hospitalised vs. out-patient) 3.14 (1.33–7.41) 0.009
Insomnia Sex (male vs. female) 0.46 (0.33–0.66) <.001
Diarrhoea No signiﬁcant predictors
Constipation Age (per 10 year) 1.47 (1.22–1.78) <.001
Financial difﬁculties Age (per 10 year) 0.76 (0.65–0.89) <.001
CL, conﬁdence limits; CLL, chronic lymphocytic leukaemia; CML, chronic myeloid leukaemia; AML, acute myeloid leukaemia.
1Variables in the ﬁnal model of the logistic regression.
2An odds ratio above 1 reﬂects more functional limitations or more symptoms.
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was only a signiﬁcant predictor of one scale in the multi-
variate analysis: patients with multiple myeloma had
more reduced role function. Finally, patients with shorter
education (as opposed to longer education) reported
more reduced cognitive function (see Table 3).
Discussion
This nationally representative, cross-sectional study
assessed a random sample of patients with multiple mye-
loma, leukaemia or lymphoma (stage 3 or 4) seen at
Danish hospitals, mainly departments of haematology at
university hospitals, within the previous year. The study
showed that most of the symptoms and problems
assessed were frequent. Using the cut-off values the most
prevalent symptoms and problems were fatigue (55%;
severe 20%), reduced role function (49%; severe 23%),
insomnia (46%; severe 15%), pain (37%; severe 15%),
and dyspnoea (36%; severe 15%). This indicates that
efforts to improve the management should be given high
priority.
The ﬁgures above do not take into consideration the
potential co-morbidity of the patients. As such, the ﬁg-
ures show the symptoms and problems experienced by
this population regardless of their aetiology, and thus, of
course, not everything can be attributed to a haemato-
logical disease.
No previous studies have included a patient sample
similar to ours, and therefore comparisons are difﬁcult.
A study of CLL patients who were not receiving current
anti cancer treatment (12) showed similar levels of symp-
toms and problems as the CLL patients in our study, al
though the women of that study generally had higher
levels of symptoms and problems whereas the males gen-
erally had lower levels.
In a study of AML patients (13) the reported levels of
symptoms and problems at the end of in-patient treat-
ment were similar to those reported by the AML patients
in our study. However, our patients had less appetite
loss, nausea and dyspnoea, and better social function.
This may reﬂect that some of the patients included in
our study had been without treatment for a long time.
A Norwegian study of Hodgkin’s lymphomas survi-
vors (20) found levels of symptoms and problems that
were generally lower than found for the Hodgkin group
in our study. This probably reﬂects that our study only
included patients with advanced lymphomas. In addition,
our study included patients in all disease phases and
thus, some of the patients’ experienced treatment-related
symptoms. However, the level of dyspnoea and constipa-
tion was higher in the Norwegian study.
A Nordic study of patients with multiple myeloma
(14) generally showed higher levels of symptoms and
problems before patients began treatment than showed
for the myeloma patients in the present study (14). The
level of symptoms and problems after 6 months of treat-
ment reported in the study by Wisloffs et al.(14) were
similar to our ﬁndings.
It is difﬁcult to interpret our results by comparing
them with the few, relevant other studies conducted,
since there are substantial differences in the sampling of
patients. The most important way to interpret our
results, from a clinical perspective, is probably done by a
careful examination of the prevalences of symptoms and
problems in the various subgroups.
Predictors of symptoms and problems
Age was a strong predictor of several symptom and func-
tion scales with older patients having more symptoms
and problems. This is consistent with ﬁndings from gen-
eral populations, where older age is associated with more
symptoms and problems (21–23), and older age has also
been associated with lower quality of life in two studies
of CLL patients (6, 12). In contrast, studies of advanced
cancer patients have generally found that younger
patients are more burdened by symptoms and problems
(24–28), and younger patients reported more depression
and worse emotional and social function in a study of
CLL patients (11). Thus, results of the present study
draw attention to the symptom-burden of the older
patients, but the social and emotional strain of disease of
younger patients should not be forgotten.
Patients in active treatment had more symptoms and
problems. This is consistent with previous ﬁndings in
haematology (29), and in cancer in general (25, 30).
Recently hospitalised patients had more nausea and
appetite loss than out-patients, which is an important ﬁnd-
ing. It indicates that identiﬁcation and treatment of these
symptoms for especially hospitalised patients is needed.
Patients with multiple myeloma generally had the
highest level of symptoms and problems. This may reﬂect
that multiple myeloma is characterised by distress due to
bone pain, pathological bone fractures and recurrent
infections (14). However, in the multivariate analysis,
patients with multiple myeloma only were signiﬁcantly
more reduced in role function. A possible reason may
be, that patients with multiple myeloma generally were
older than patients with all other diagnoses (except
CLL), and older age showed to be a strong predictor.
Patients diagnosed with AML showed the lowest level of
symptoms and problems. This is consistent with the ﬁnd-
ings from a study that compared patients with acute leu-
kaemia to patients with advanced Hodgkin’s lymphoma
5 years after treatment, and found that Hodgkin’s
patients had signiﬁcantly greater psychological distress
and greater fatigue (31).
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had more insomnia than men. This is consistent with
ﬁndings from general populations (21–23), and has also
been found in CLL patients (12, 29), and in adult leukae-
mia survivors (32). However, a study of Hodgkin’s lym-
phomas survivors found that women had less fatigue and
better quality of life (20).
Previous studies have shown that highly educated
patients have fewer symptoms and problems (24, 25, 30,
33), and in a study of adult leukaemia survivors patients
with less education reported worse overall adjustment
(32). Surprisingly, education was related to cognitive
function only in this study. Hence, the study only par-
tially supports the notion that there are social inequali-
ties in the prevalence of symptoms and problems. It has
previously been found that unmarried patients with
advanced cancer have more symptoms and problems (25,
26), but this was neither supported in the present study
nor in a study of adult leukaemia survivors (32).
Strengths and limitations
A major strength of this study is that we included an
almost representative, national sample of patients with
lymphoma (stage 3 or 4), leukaemia and multiple mye-
loma who have been in contact with a hospital depart-
ment within the previous year. The participation of
hospital departments was relatively high: all haematolog-
ical departments in the selected regions participated, and
we reviewed the majority of the medical records from the
patients identiﬁed. However, there is an under-represen-
tation of patients coming from the rural region ‘Ring-
koebing’ because some patients from this region are
referred to a specialised department of haematology in a
region not included in the study.
Given the representativeness of the patients included,
the study gives a picture of the burden of symptoms and
problems in haematological patients in contact with a
hospital department. The important message is that these
patients do have symptoms and problems that do deserve
attention and resources in the health care system.
There are three primary weaknesses of the study. First,
not all patients participated. A response rate of 64% is
not optimal. However, it is within the range of what is
often found in cross-sectional surveys with mailed self-
assessment questionnaires (11, 34–36) and it is impossible
to avoid some non-participation in such studies. If
patients had been approached in person and⁄or we had
used structured interviews we might have achieved a bet-
ter response rate, but this was not feasible with our
design. The oldest patients participated least in the study
and together with the fact that the most burdened
patients are the ones least likely to participate, this
means that the study probably underestimates symptoms
and problems. However, this does not jeopardise the pri-
mary conclusion of the paper: that there is a substantial
prevalence of symptoms and problems in this group of
patients.
Second, the fact that we included patients irrespective
of diagnoses, treatment, etc. made it more difﬁcult to sub-
divide patients in clinically well characterised subgroups
than if a highly selected subgroup of patients was
included. For example, we found it impossible to devise
classiﬁcations of treatments that were applicable across
the diverse spectrum of diagnoses and treatment phases.
Knowledge about the effect of speciﬁc treatments on qual-
ity of life must be obtained from studies designed for this.
Third, due to space limitations in the questionnaire
(we were afraid the response burden was already signiﬁ-
cant) we did not collect data on co-morbidity, which
would have been beneﬁcial, and it is a limitation of the
study that we are not able to control for this potential
confounder. On the other hand, for the primary purpose
of this study, co-morbidity did not seem crucial. Patients
need attention to and care for their experienced symp-
toms and problems regardless of aetiology.
Conclusion
This is probably the ﬁrst nationally representative study
of symptoms, problems and quality of life in haemato-
logical patients. These patients have symptoms and prob-
lems that deserve attention, and older patients and
patients undergoing treatment are especially burdened.
The study found little evidence of social inequalities in
HRQOL. The study indicates that haematological malig-
nancies affect HRQOL broadly and points to the chal-
lenge of alleviating this impact on HRQOL.
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